Sponsors (13)
The bill increases patient safety and FDA oversight by limiting large‑scale compounding and improving registration, reporting, and funding, but does so at the cost of reduced access for some patients, added compliance costs for compounding providers, and potential higher fees and short‑term supply disruptions.
Patients with chronic conditions gain stronger protection because the bill limits widespread compounding of marketed drugs and steers use toward FDA‑approved products, reducing risk of ineffective or unsafe copies.
Patients and health systems benefit from expanded FDA oversight (registration, traceability, and risk‑based inspections of outsourcing facilities), improving detection and prevention of contamination or substandard compounded drugs.
Prescribing practitioners get a clearer standard to justify when patient‑specific compounding is required (a 'significant difference'), which can support clinical decisions to pursue necessary compounded therapy.
Patients who rely on individualized compounded medications (especially chronic patients) may face reduced access if prescribers exceed the 20/month cap or if compounded options are restricted.
Community compounding pharmacies and outsourcing facilities could lose revenue or be forced to scale back services due to the cap, registration/inspection requirements, and potential fee increases, threatening local access and small businesses.
Pharmacies, outsourcing facilities, and prescribers that frequently compound for out‑of‑state patients will face added administrative and compliance costs to track counts and submit regular reports.
Based on analysis of 5 sections of legislative text.
Limits compounding of drugs that copy commercial products, mandates reporting and inspections for high‑volume compounders, removes an outsourcing exemption, and lets FDA set a base safety fee.
Limits how often pharmacies may compound copies of commercially available drugs, requires annual reporting when compounding for out‑of‑state patients exceeds set thresholds, increases FDA inspection requirements for high‑volume outsourcing facilities, removes a registration exemption for outsourcing facilities, and gives the FDA discretion to set a base fee to cover safety activities for compounded drugs. Some changes take effect on enactment, reporting begins in calendar year 2025, and inspection/registration changes apply six months after enactment.
Introduced December 9, 2025 by Rudy Yakym · Last progress December 9, 2025